Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:etoricoxib
|
| gptkbp:approvalYear |
2002
|
| gptkbp:ATCCode |
M01AH05
|
| gptkbp:brand |
gptkb:etoricoxib
|
| gptkbp:CASNumber |
202409-33-4
|
| gptkbp:chemicalFormula |
C18H15ClN2O2S
|
| gptkbp:contraindication |
gptkb:inflammatory_bowel_disease
congestive heart failure severe liver impairment active peptic ulcer |
| gptkbp:drugClass |
gptkb:nonsteroidal_anti-inflammatory_drug
|
| gptkbp:eliminationHalfLife |
22 hours
|
| gptkbp:form |
gptkb:tablet
120 mg 30 mg 60 mg 90 mg |
| gptkbp:indication |
pain and inflammation management
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:mechanismOfAction |
selective COX-2 inhibition
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionRequired |
available from Merck & Co.
|
| gptkbp:riskFactor |
gastrointestinal side effects
renal impairment cardiovascular events |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
edema abdominal pain dizziness headache hypertension dyspepsia increased risk of cardiovascular events |
| gptkbp:status |
approved in many countries
not approved in the United States |
| gptkbp:synonym |
gptkb:etoricoxib
|
| gptkbp:usedFor |
osteoarthritis
pain relief rheumatoid arthritis acute pain chronic musculoskeletal pain ankylosing spondylitis acute gout |
| gptkbp:bfsParent |
gptkb:MRK
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Arcoxia
|